Latest Orthocell Limited News

Page 4 of 4

Orthocell Surges with Record $2.21M Revenue and US FDA Submission

Orthocell Limited has reported a third consecutive quarter of record revenue, driven by strong sales growth and strategic market expansions, including a key US FDA submission for its nerve repair product Remplir™.

Ada Torres

15 Jan 2025

Browse the archive

Full archive

Oct 2026 Sept 2026 Aug 2026 July 2026 June 2026 May 2026 Apr 2026 Mar 2026